The transaction is expected to be complete by the first quarter of 2022. The acquisition is expected to increase Boston Scientific's electrophysiology and structural heart product portfolios for including the radiofrequency (RF) NRG and Versa Cross Transseptal Platforms, and also a family of guidewires, sheaths and dilators for supporting left heart access.

 Mike Mahoney, chairman and chief executive officer, Boston Scientific, said in a statement that the talented and innovative Baylis Medical Company team when combined with these transseptal platforms would enhance the company’s efforts to improve procedural efficiencies with physician tools designed to make access to the left atrium safer and more predictable, with a focus on outcomes. They believed that Baylis Medical Company will add meaningful revenue, operating income, and new research and development capabilities across various Boston Scientific businesses, and also complementing existing offerings within the company’s electrophysiology and structural heart portfolios.

Baylis Medical Company was thrilled to commit with Boston scientific and will further enhance efforts to bring these technologies to a greater number of physicians and patients with their significant global reach, according to Kris Shah, president of Baylis Medical Company. He also said that they were looking forward to increase investments in Baylis Medical Technologies business and in Canada’s rich medical technology industry.

Baylis Medical Company designs cardiac related medical devices in the field of cariology and Baylis Medical technologies manufactures medical devices for the field of radiology and neurology.


Investigation Modality,Electrophysiology,Electrophysiologic testing



Investigation Modality,Electrophysiology,Electrophysiologic Testing